Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertugliflozin + sitagliptin vs monotherapy in type 2 diabetes inadequately controlled on metformin
2013-003698-82Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Ertugliflozin + sitagliptin + metformin, Ertugliflozin + metformin and Sitagliptin + metformin (3 arms). Primary endpoint: Body weight. Started Apr 2014; status: completed.
02
Drugs
ertugliflozinsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-003698-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003698-82.